Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The New England Journal of Medicine, 2023
Dietary Fiber, Atherosclerosis, and Cardiovascular Disease
doi:10.1016/j.eclinm.2025.103213
Overall, both medications offer new hope in the domain of weight and glucose management, signaling a shift towards more integrated therapeutic strategies
Accelerated kidney aging promotes diabetic kidney disease
We understand that weight management is a journey requiring consistent support, not just a one-time prescription
US$ 20.47
US$ 27.69
US$ 22.78
US$ 27.73
US$ 21.68
US$ 22.01
